Althea to manufacture Althus' ALTU-238 for Ph III trial
Althea Technologies, a provider of innovative technologies and services for pharmaceutical development and manufacturing, has won a contract from fellow USA-based Altus Pharmaceuticals to produce its ALTU-238 product candidate, a crystallized formulation of human growth hormone that is designed to be administered once-weekly through a fine gauge needle for the treatment of HGH disorders.
Altus, a Cambridge, Massachussetts-based biopharmaceutical company, is focused on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders.
Althea Technologies says it will manufacture the Phase III clinical trial material of ALTU-238 human growth hormone in its newly-expanded certified Good Manufacturing Practices facilities at its San Diego, California campus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze